Table 2 Clinical characteristics and lung function parameters in different treatment groups
BDP/F extrafine pMDI (n = 53) | BUD/F and FP/S DPI (n = 58) | |
|---|---|---|
Male, n (%) | 15 (28.3%) | 15(25.8%) |
Age, years (mean and range) | 48 (19-84) | 47 (18-86) |
Current smokers, n (%) | 20 (37.7%) | 19 (32.8%) |
Allergies, n (%) | 40 (75.5%) | 41 (70.6%) |
Patients using SABA for as needed medication, n (%) | 53 (100%) | 50 (86.2%) |
Patients using BUD/F for as needed medication, n (%) | 0 (0%) | 8 (13.8%) |
Initial diagnosis of mild persistent asthma, n (%) | 0 (0%) | 0 (0%) |
Initial diagnosis of moderate persistent asthma, n (%) | 45 (84.9%) | 49 (84.5%) |
Initial diagnosis of severe persistent asthma, n (%) | 8 (15.1%) | 9 (15.5%) |
FEV1(mean ± SE; % of predicted) | 81.71 ± 17.53 | 79.38 ± 17.71 |
PEF (mean ± SE; % of predicted) | 78.47 ± 19.92 | 75.34 ± 22.12 |
FEF 25-75 (mean ± SE; % of predicted) | 62.35 ± 26.18 | 56.52 ± 23.3 |
MEF 75 (mean ± SE; % of predicted) | 71.53 ± 28.38 | 71.41 ± 29.01 |
MEF 25 (mean ± SE; % of predicted) | 58.2 ± 26.12 | 53.74 ± 24.23 |